Cargando…

Eugenol triggers apoptosis in breast cancer cells through E2F1/survivin down-regulation

BACKGROUND: Breast cancer is a major health problem that threatens the lives of millions of women worldwide each year. Most of the chemotherapeutic agents that are currently used to treat this complex disease are highly toxic with long-term side effects. Therefore, novel generation of anti-cancer dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Sharif, Ibtehaj, Remmal, Adnane, Aboussekhra, Abdelilah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931838/
https://www.ncbi.nlm.nih.gov/pubmed/24330704
http://dx.doi.org/10.1186/1471-2407-13-600
_version_ 1782304724305838080
author Al-Sharif, Ibtehaj
Remmal, Adnane
Aboussekhra, Abdelilah
author_facet Al-Sharif, Ibtehaj
Remmal, Adnane
Aboussekhra, Abdelilah
author_sort Al-Sharif, Ibtehaj
collection PubMed
description BACKGROUND: Breast cancer is a major health problem that threatens the lives of millions of women worldwide each year. Most of the chemotherapeutic agents that are currently used to treat this complex disease are highly toxic with long-term side effects. Therefore, novel generation of anti-cancer drugs with higher efficiency and specificity are urgently needed. METHODS: Breast cancer cell lines were treated with eugenol and cytotoxicity was measured using the WST-1 reagent, while propidium iodide/annexinV associated with flow cytometry was utilized in order to determine the induced cell death pathway. The effect of eugenol on apoptotic and pro-carcinogenic proteins, both in vitro and in tumor xenografts was assessed by immunoblotting. While RT-PCR was used to determine eugenol effect on the E2F1 and survivin mRNA levels. In addition, we tested the effect of eugenol on cell proliferation using the real-time cell electronic sensing system. RESULTS: Eugenol at low dose (2 μM) has specific toxicity against different breast cancer cells. This killing effect was mediated mainly through inducing the internal apoptotic pathway and strong down-regulation of E2F1 and its downstream antiapoptosis target survivin, independently of the status of p53 and ERα. Eugenol inhibited also several other breast cancer related oncogenes, such as NF-κB and cyclin D1. Moreover, eugenol up-regulated the versatile cyclin-dependent kinase inhibitor p21(WAF1) protein, and inhibited the proliferation of breast cancer cells in a p53-independent manner. Importantly, these anti-proliferative and pro-apoptotic effects were also observed in vivo in xenografted human breast tumors. CONCLUSION: Eugenol exhibits anti-breast cancer properties both in vitro and in vivo, indicating that it could be used to consolidate the adjuvant treatment of breast cancer through targeting the E2F1/survivin pathway, especially for the less responsive triple-negative subtype of the disease.
format Online
Article
Text
id pubmed-3931838
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-39318382014-02-23 Eugenol triggers apoptosis in breast cancer cells through E2F1/survivin down-regulation Al-Sharif, Ibtehaj Remmal, Adnane Aboussekhra, Abdelilah BMC Cancer Research Article BACKGROUND: Breast cancer is a major health problem that threatens the lives of millions of women worldwide each year. Most of the chemotherapeutic agents that are currently used to treat this complex disease are highly toxic with long-term side effects. Therefore, novel generation of anti-cancer drugs with higher efficiency and specificity are urgently needed. METHODS: Breast cancer cell lines were treated with eugenol and cytotoxicity was measured using the WST-1 reagent, while propidium iodide/annexinV associated with flow cytometry was utilized in order to determine the induced cell death pathway. The effect of eugenol on apoptotic and pro-carcinogenic proteins, both in vitro and in tumor xenografts was assessed by immunoblotting. While RT-PCR was used to determine eugenol effect on the E2F1 and survivin mRNA levels. In addition, we tested the effect of eugenol on cell proliferation using the real-time cell electronic sensing system. RESULTS: Eugenol at low dose (2 μM) has specific toxicity against different breast cancer cells. This killing effect was mediated mainly through inducing the internal apoptotic pathway and strong down-regulation of E2F1 and its downstream antiapoptosis target survivin, independently of the status of p53 and ERα. Eugenol inhibited also several other breast cancer related oncogenes, such as NF-κB and cyclin D1. Moreover, eugenol up-regulated the versatile cyclin-dependent kinase inhibitor p21(WAF1) protein, and inhibited the proliferation of breast cancer cells in a p53-independent manner. Importantly, these anti-proliferative and pro-apoptotic effects were also observed in vivo in xenografted human breast tumors. CONCLUSION: Eugenol exhibits anti-breast cancer properties both in vitro and in vivo, indicating that it could be used to consolidate the adjuvant treatment of breast cancer through targeting the E2F1/survivin pathway, especially for the less responsive triple-negative subtype of the disease. BioMed Central 2013-12-13 /pmc/articles/PMC3931838/ /pubmed/24330704 http://dx.doi.org/10.1186/1471-2407-13-600 Text en Copyright © 2013 Al-Sharif et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Al-Sharif, Ibtehaj
Remmal, Adnane
Aboussekhra, Abdelilah
Eugenol triggers apoptosis in breast cancer cells through E2F1/survivin down-regulation
title Eugenol triggers apoptosis in breast cancer cells through E2F1/survivin down-regulation
title_full Eugenol triggers apoptosis in breast cancer cells through E2F1/survivin down-regulation
title_fullStr Eugenol triggers apoptosis in breast cancer cells through E2F1/survivin down-regulation
title_full_unstemmed Eugenol triggers apoptosis in breast cancer cells through E2F1/survivin down-regulation
title_short Eugenol triggers apoptosis in breast cancer cells through E2F1/survivin down-regulation
title_sort eugenol triggers apoptosis in breast cancer cells through e2f1/survivin down-regulation
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931838/
https://www.ncbi.nlm.nih.gov/pubmed/24330704
http://dx.doi.org/10.1186/1471-2407-13-600
work_keys_str_mv AT alsharifibtehaj eugenoltriggersapoptosisinbreastcancercellsthroughe2f1survivindownregulation
AT remmaladnane eugenoltriggersapoptosisinbreastcancercellsthroughe2f1survivindownregulation
AT aboussekhraabdelilah eugenoltriggersapoptosisinbreastcancercellsthroughe2f1survivindownregulation